- Home
- ADCT vs FTW Comparison
ADCT vs FTW Comparison
Compare ADCT & FTW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ADCT | FTW |
|---|---|---|
| Founded | 2011 | 2017 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Oil & Gas Production |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 484.4M | 470.2M |
| IPO Year | 2019 | 2024 |
Fundamental Metrics
Financial Performance| Metric | ADCT | FTW |
|---|---|---|
| Price | $4.55 | $10.95 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $7.75 | N/A |
| AVG Volume (30 Days) | ★ 741.8K | 111.2K |
| Earning Date | 05-13-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 30.86 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $81,357,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $66.49 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 14.85 | N/A |
| 52 Week Low | $1.20 | $9.50 |
| 52 Week High | $4.98 | $17.20 |
Technical Indicators
Market Signals| Indicator | ADCT | FTW |
|---|---|---|
| Relative Strength Index (RSI) | 67.39 | 48.82 |
| Support Level | $3.28 | $9.50 |
| Resistance Level | $4.77 | $13.83 |
| Average True Range (ATR) | 0.27 | 0.52 |
| MACD | 0.08 | -0.02 |
| Stochastic Oscillator | 78.31 | 53.31 |
Price Performance
Historical ComparisonAbout ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).
About FTW EQV Ventures Acquisition Corp. Class A Ordinary Shares
EQV Ventures Acquisition Corp is a blank check company.